Table of Contents
Pathophysiology of Metastatic Bone Disease and the Role of Bisphosphonates
Clinical Importance and Prognosis of Bone Metastases
Skeletal Complications in Metastatic Bone Disease Are Significant
Pathophysiology of Bone Metastases
Cancer and Bone Cell Interactions
Bone Remodelling Cancer Effects
Bone Markers in Osteolytic and Osteosclerotic Metastatic Bone Disease
Consequences of Increased Bone Resorption
Treatment of Bone Metastases
Bisphosphonate Pharmacology
Prevention of Skeletal-Related Events Phase III Pamidronate Studies
Proportion of Patients Having SREs Pooled Breast Cancer Clinical Trials (N = 756)
Proportion of Patients Having SREs Multiple Myeloma (N = 377)
Total Number of SREs Recorded During Randomised Clinical Trials of Pamidronate
Effects of Pamidronate on Pain and Analgesic Consumption
Prostate Cancer and Other Tumours
PPT Slide
Adverse Events Profile of Pamidronate
Zoledronic Acid
PPT Slide
PPT Slide
ZOMETAŽ Key Clinical Pharmacology Properties
Phase II Study (007) Results Support ZOMETAŽ 4-mg Infusion Every 3 to 4 Wk
Urinary N-telopeptide/Creatinine Ratio After the First and Subsequent (q4 wk) Doses of ZOMETAŽ (Study 007)
Efficacy in Hypercalcaemia of Malignancy
Conclusions
|